Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC). (December 2016) - Meric-Bernstam, F.; Tannir, N.; Harding, J.; Voss, M.; Mier, J.; DeMichele, A.; Munster, P.; Patel, M.; Iliopoulos, O.; Owonikoko, T.; Whiting, S.; Orford, K.; et al.